Press Releases

Press Releases

Share
Print
Share
Print
and/or
272 Press Releases found

Young Investigators Named Winners of 2019 Paul Marks Prize for Cancer Research

MSK award recognizes promising investigators for their efforts in advancing cancer research.

  • Tuesday, November 12, 2019

Claus Torp Jensen Has Been Appointed First Chief Digital Officer and Head of Technology for Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology.

  • Monday, October 14, 2019

Neuro-Oncologist Lisa M. DeAngelis Has Been Named Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering Cancer Center

After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.

  • Tuesday, September 10, 2019

Study on Sexual Harassment and Gender Disparities Among Gynecologic Oncologists Highlighted in ASCO’s 2019 Press Program

Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared new data from a survey of members of the Society of Gynecologic Oncology (SGO) showing that sexual harassment and observed gender discrimination continue to be significant issues in the medical community. The results of the study found that more than 60 percent of gynecologic oncologists had experienced sexual harassment, while only 10 percent of survey respondents reported the incident. The findings were presented as part of the press program for this year’s annual meeting of the American Society of Clinical Oncology (ASCO).

  • Monday, June 3, 2019

Michael P. Harrington Named Executive Vice President and Chief Financial Officer at Memorial Sloan Kettering Cancer Center

Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.

  • Wednesday, April 10, 2019

Cancer Care Redefined: Memorial Sloan Kettering Unveils New Nassau County Site

Memorial Sloan Kettering Cancer Center (MSK) announced its recommitment to communities across Long Island today with the dedication of MSK Nassau, a light-filled 114,000-square-foot outpatient cancer treatment facility centrally located along Hempstead Turnpike. MSK’s newest location, and its third on Long Island, will open for patient care on April 8 with more than 180 dedicated medical and professional staff, all of whom are MSK employees.

  • Thursday, April 4, 2019

The Starr Foundation Reaffirms Support for Stem Cell Research with $50 Million Gift

The Starr Foundation is continuing its longstanding commitment to stem cell research in New York City with a $50 million gift in support of the Tri-Institutional Stem Cell Initiative (Tri-SCI), a research collaboration between Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine.

  • Thursday, April 4, 2019

Following Milestone FDA Approval, MSK Researchers Address Resistance to Larotrectinib through Next-Generation TRK-Targeted Therapeutic

LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.

  • Monday, April 1, 2019

Novel Memorial Sloan Kettering Study on CAR T Cell Therapy in Solid Tumors Highlighted in American Association for Cancer Research Annual Meeting Press Program

— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.

  • Sunday, March 31, 2019

New Study Reveals Gut Microbes May Help Protect People Having a Bone Marrow Transplant

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.

  • Sunday, December 2, 2018